Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report

Author(s): Andromachi Makri, Matilda Florentin*, Moses S. Elisaf and George Liamis

Volume 14, Issue 3, 2019

Page: [238 - 241] Pages: 4

DOI: 10.2174/1574886314666190307142111

Abstract

Objective: Olmesartan-induced enteropathy consists a syndrome that mimics celiac disease both clinically and histologically. Cases of this entity have sporadically been reported since 2012 and are usually characterized by severe diarrhea and malabsorption, followed by significant weight loss.

Case Report: Herein, we report an uncommon case of this syndrome, where weight loss preceded several months the onset of gastrointestinal symptoms.

Discussion and Conclusion: Physicians should be aware of unexplained weight loss in patients taking olmesartan, as prompt discontinuation of the drug may prevent the deleterious consequences of malabsorption.

Keywords: Enteropathy, olmesartan, weight loss, ARB, computed tomography, IgA.

« Previous Next »
Graphical Abstract

[1]
Kourlaba G, Gialama F, Tsioufis K, Maniadakis N. A literature review to evaluate the clinical and economic value of olmesartan for the treatment of hypertensive patients. Int J Cardiol 2016; 221: 60-74.
[2]
Rubio-Tapia A, Herman ML, Ludvigsson JF, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 2012; 87: 732-8.
[3]
Adike A, Corral J, Rybnicek D, et al. Olmesartan-induced enteropathy. Methodist DeBakey Cardiovasc J 2016; 12: 230-2.
[4]
Hujoel IA, Rubio-Tapia A. Sprue-Like Enteropathy associated with olmesartan: A new kid on the enteropathy block. GE Port J Gastroenterol 2016; 23: 61-5.
[5]
Scialom S, Malamut G, Meresse B, et al. Gastrointestinal Disorder Associated with olmesartan mimics autoimmune enteropathy. PLoS One 2015; 10: e0125024.
[6]
Carneiro L, Moreira A, Pereira A, et al. Olmesartan-induced sprue like Enteropathy. GE Port J Gastroenterol 2016; 23: 101-5.
[7]
Gonakoti S, Khullar S, Rajkumar A. Olmesartan associated enteropathy: A rare underdiagnosed cause of diarrhea and weight loss. Am J Case Rep 2019; 20: 111-6.
[8]
Henry P, Dano H, Piessevaux H, Jouret-Mourin A. An unusual case of olmesartan induced enteropathy. Ann Pathol 2019; 39(3): 237-40.
[9]
Onteddu NK, Pulivarthi V, Ginnavaram M, Kedika R. Olmesartan-induced Enteropathy BMJ Case Rep 2018;. 2018. pii: bcr-2018-224411
[10]
Nagashima K, Katsurada T, Sakamoto N. A case of olmesartan-associated sprue-like Enteropathy. Clin Gastroenterol Hepatol 2018; 16: A45-6.
[11]
Karakonstantis S, Tzagkarakis E, Giannikaki E, Paspatis G. Olmesartan-associated enteropathy. A rare but easily treatable entity. Acta Gastroenterol Belg 2017; 80: 541-3.
[12]
Machado I, Reolid M, Martinez de Juan F, Martinez Lapiedra C, Maia de Alcantara F. Sprue-like enteropathy associated with olmesartan in a patient with villous atrophy, HLA-DQ2 genotype and antinuclear antibodies. Rev Esp Enferm Dig 2016; 108: 732-3.
[13]
Galanopoulos M, Varytimiadis L, Tsigaridas A, et al. Small bowel enteropathy associated with olmesartan medoxomil treatment. Ann Gastroenterol 2017; 30: 131-3.
[14]
Lourenco LC, Carvalho EBJ, Santos L, Martins A, Reis J. Sprue-like enteropathy associated with olmesartan: An unrecognized emerging drug-induced enteropathy? GE Port J Gastroenterol 2016; 23: 335-6.
[15]
Desruisseaux C, Bensoussan M, Desilets E, et al. Adding water to the mill: Olmesartan-induced collagenous sprue-a case report and brief literature review. Can J Gastroenterol Hepatol 2016; 2016: 4837270.
[16]
FDA Drug Safety Communication: FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. Available from:. https://www.fda.gov/Drugs/DrugSafety/ucm359477.htm [Last assessed February 24, 2019]
[17]
Basson M, Mezzarobba M, Weill A, et al. Severe intestinal malabsorption associated with olmesartan: A French nationwide observational cohort study. Gut 2016; 65: 1664-9.
[18]
Talley NJ. Use of olmesartan for >/= 1 year was associated with hospitalization for intestinal malabsorption. Ann Intern Med 2015; 163: JC13.
[19]
Marthey L, Cadiot G, Seksik P, et al. Olmesartan-associated enteropathy: Results of a National Survey. Aliment Pharmacol Ther 2014; 40: 1103-9.
[20]
Herman ML, Rubio-Tapia A, Wu TT, Murray JA. A Case of severe sprue-like enteropathy associated with valsartan. ACG Case Rep J 2015; 2: 92-4.
[21]
Negro A, De Marco L, Cesario V, et al. A case of moderate sprue-like enteropathy associated with telmisartan. J Clin Med Res 2017; 9: 1022-5.
[22]
Dong YH, Jin Y, Tsacogianis TN, et al. Use of olmesartan and enteropathy outcomes: A multi-database study. Aliment Pharmacol Ther 2018; 47: 792-800.
[23]
Martins C, Teixeira C, Ribeiro S, et al. Seronegative intestinal villous atrophy: A diagnostic challenge. Case Rep Gastrointest Med 2016; 2016: 6392028.
[24]
Abdelghany M, Gonzalez L 3rd, Slater J, Begley C. Olmesartan associated sprue-like enteropathy and colon perforation. Case Rep Gastrointest Med 2014; 2014: 494098.
[25]
Uehara T, Ikusaka M, Ohira Y, et al. Olmesartan-induced enteropathy manifesting as Wernicke-Korsakoff Syndrome. Intern Med 2016; 55: 3675-8.
[26]
Non-Alcoholic Fatty Liver Disease Study Group, Dolci M, Nascimbeni F, et al.. Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. Dig Liver Dis 2016; 48: 1399-401.
[27]
Kulai T, Arnason T, MacIntosh D, Igoe J. Duodenal villous atrophy in a ttg-negative patient taking olmesartan: A case report and review of the literature. Can J Gastroenterol Hepatol 2016; 2016: 6091571.
[28]
Hammoudi N, Dior M, Giraud V, Coffin B. Olmesartan-induced enteropathy associated with cutaneous lesions. Clin Case Rep 2016; 4: 379-82.
[29]
Marietta EV, Nadeau AM, Cartee AK, et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther 2015; 42: 1303-14.

Rights & Permissions Print Cite
Article Metrics
37
5
1
1
© 2024 Bentham Science Publishers | Privacy Policy